IN8bio

Exciting data from our Phase 1 INB-200 program presented in an oral session this weekend at ASCO2025! I heard great feedback from KOLs across the country as we try to make a real impact for these patients with GBM. Please join us on a conference call at 8:30am EDT as we review the data where median PFS for patients receiving repeated doses surpassed historical median OS for standard-of-care.

When we founded IN8bio, the idea was simple but ambitious: bring smarter, safer cell therapies to patients who need better options. Glioblastoma is one of the deadliest cancers, with virtually no progress in over two decades. Many told us not to bother because it was too hard, too small, too costly, or just because it's impossible. But for patients like Jim and their families, that’s not an acceptable answer. Jim’s inspiring story shows what’s possible when science, perseverance, and courage come together. It’s a testament to innovation, to the vision of our scientific team, and to the dedication of physicians who refuse to give up. We're still in the fight to find a path forward. Join us in a few weeks for an update at ASCO2025. We’re proud of what our team and partners have accomplished, but the fight is far from over. Patients are still waiting. This is why we do what we do.

Thanks to @KarenJagoda for inviting me on her Empowered Patient Podcast to talk about @In8bio’s mission and how gamma-delta T cells are one of the most exciting frontiers in immunotherapy. We’re building smarter, and potentially safer and more effective therapies for cancer & autoimmune disease.   Full interview here: empoweredpatientradio.com/ga…

A big thank you to #IO360, Kate Woodard, @AxelHoos and Valerie Bowling for giving me the opportunity to share why I think @In8bio is taking a fundamentally different approach in the race to bring a new therapy to autoimmune diseases. By my last count, over 45 programs are chasing CD19 CAR-T for autoimmunity. But few are asking tough questions about safety, scalability, or patient access. At IN8bio, we chose not to follow the herd. Instead, we’ve built something new: a gamma-delta T cell engager designed to deeply deplete B cells potentially without the toxicity seen with CAR-T or traditional CD3-based engagers. We think this is important for a number of reasons: • Many CAR-T trials quietly avoid enrolling women due to lymphodepletion risks—especially permanent ovarian damage. • There are a huge number of commercial and operational challenges around delivering complex CAR-T therapies in autoimmune settings, especially across multiple siloed departments in hospitals (hematology, rheumatology, etc.). • T cell engagers offer a simpler, potentially safer, and more scalable path—but most γδ approaches to date haven’t worked due to poor expansion. We may have cracked the code. Our INB-619 candidate has been shown to deliver significant expansion of γδ T cells, with robust B cell killing and no IL-6 spike—which could mean no CRS or ICANS. This is a major moment of opportunity, and risk for companies entering autoimmunity. Thoughtful design, commercially attractive profiles and a path to patients will separate the real contenders. #CancerZero

I wanted to express my sincere gratitude to @Asthika at Truist for an exceptional dinner last night, and a thank you to Dr. Georg Schett for his captivating talk at this year’s #IO360 conference. I eagerly anticipate the incredible opportunities that lie ahead!

Yesterday we presented at TD Cowen—excited to unveil INB-600, our next-gen γδ T cell engager! • TCEs are a billion-dollar success in immunotherapy (J&J, Roche) • INB-619 not only engages γδ T cells but expands them for a stronger, longer-lasting immune response • Designed for blood cancers & autoimmune diseases with a potentially safer, more effective approach than CD3-based TCEs A game-changer for γδ T cell therapies. More to come! $INAB

So proud of the @In8bio team and truly honored to partner with Dr. McGuirk and the whole @KUCancerCenter team. Together we are working towards our mission of achieving Cancer Zero and making a difference for leukemia patients!

Wrapping up #JPM2025, the mood seemed quite dour, especially on the buy side. However, starting the week on the oncology panel for #BiotechShowcase, I'm optimistic! Many are advancing innovative science to make a difference for cancer patients. Thanks to the great panel members including @pmunstermd, Mo Trikha, @histosonics, Joel Sandler, and @MyOncology. Good luck to all in 2025!

Yesterday, we proudly announced long-term PFS data in our Ph 1 trial of INB-100 allogeneic #gdTcells for #Leukemia at #ASH24. Read more: bit.ly/4iveWCU. Our entire team in collaboration with @KUcancercenter have worked hard to continue to advance this trial, bringing a potential new therapy to older adults with high-risk AML. #CancerZero is more than our Mission; it is our continued effort to bring impactful therapies to patients with severe diseases and significant unmet needs. We look forward to continued data from these patients and our expansion cohort in 2025! $INAB #CellTherapy #Oncology #ASH2024 #CellTherapy #Leukemia #AML @IN8bio